- Home
- NIM vs STRO Comparison
NIM vs STRO Comparison
Compare NIM & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIM
- STRO
- Stock Information
- Founded
- NIM 1992
- STRO 2003
- Country
- NIM United States
- STRO United States
- Employees
- NIM N/A
- STRO N/A
- Industry
- NIM Trusts Except Educational Religious and Charitable
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NIM Finance
- STRO Health Care
- Exchange
- NIM Nasdaq
- STRO Nasdaq
- Market Cap
- NIM 116.0M
- STRO 94.9M
- IPO Year
- NIM N/A
- STRO 2018
- Fundamental
- Price
- NIM $9.35
- STRO $0.80
- Analyst Decision
- NIM
- STRO Hold
- Analyst Count
- NIM 0
- STRO 7
- Target Price
- NIM N/A
- STRO $1.97
- AVG Volume (30 Days)
- NIM 35.4K
- STRO 1.7M
- Earning Date
- NIM 01-01-0001
- STRO 11-06-2025
- Dividend Yield
- NIM 3.46%
- STRO N/A
- EPS Growth
- NIM N/A
- STRO N/A
- EPS
- NIM N/A
- STRO N/A
- Revenue
- NIM N/A
- STRO $105,646,000.00
- Revenue This Year
- NIM N/A
- STRO $65.48
- Revenue Next Year
- NIM N/A
- STRO N/A
- P/E Ratio
- NIM N/A
- STRO N/A
- Revenue Growth
- NIM N/A
- STRO N/A
- 52 Week Low
- NIM $8.28
- STRO $0.52
- 52 Week High
- NIM $9.74
- STRO $4.60
- Technical
- Relative Strength Index (RSI)
- NIM 51.87
- STRO 37.50
- Support Level
- NIM $9.19
- STRO $1.01
- Resistance Level
- NIM $9.42
- STRO $1.20
- Average True Range (ATR)
- NIM 0.10
- STRO 0.12
- MACD
- NIM 0.00
- STRO -0.03
- Stochastic Oscillator
- NIM 52.00
- STRO 3.36
About NIM Nuveen Select Maturities Municipal Fund
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.